FDA Expands Pfizer's Ibrance Label For Frontline Maintenance In Advanced Breast Cancer

기사 요약

The FDA approves Pfizer's Ibrance regimen for HR+, HER2+ metastatic breast cancer maintenance after positive Phase 3 data.